RxDoctor Payments Data

Benedict Ancock, MD

Cardiovascular Disease · Larkspur, CANPI 1578847844

Payments from drug & device makers

$3,666in general payments, 2019–2025

Across 65 payments — averaging $56.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$2K
  • Edwards Lifesciences$733
  • Heartflow, Inc.$333
  • Boston Scientific$291
  • Mirum Pharmaceuticals, Inc.$151
  • Johnson & Johnson$63
  • plus $257 from 11 others

What the payments were for

  • Travel & lodging$1,54842%
  • Food & beverage$2,11958%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,666 in reported general payments places this provider in the 55th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$598,234
Medicare patients
1,881
Services billed
6,935

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban445$635,004
XareltoRivaroxaban156$200,714
MultaqDronedarone Hcl48$68,891
Repatha SureclickEvolocumab37$42,394
EntrestoSacubitril/Valsartan24$30,651
Praluent PenAlirocumab19$23,565
JardianceEmpagliflozin17$20,190
Ezetimibe304$11,395
Metoprolol Succinate615$10,770
BrilintaTicagrelor11$10,668
Atorvastatin Calcium825$9,410
VascepaIcosapent Ethyl20$8,439
Rosuvastatin Calcium529$7,838
Amlodipine Besylate528$4,452
Carvedilol ErCarvedilol Phosphate13$3,670

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$635,004445 claims
Johnson & JohnsonXarelto$63$200,714156 claims
Sanofi-aventis U.S. LLCMultaq$22$68,89148 claims
NovartisEntresto$14$30,65124 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Larkspur

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →